TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37872725

Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation (ECPR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cardiopulmonary resuscitation (CCPR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECPR
Number of subjects: 0
Study: 37872763

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic period (May to December 2021)
Number of subjects: 22650

Group type: COMPARATOR
Intervention: Pre-COVID-19 period (January 2018 to April 2020)
Number of subjects: 22650

Group type: EXPERIMENTAL
Intervention: Healthcare system capacity during COVID-19
Number of subjects: 22650
Study: 37873555

Group type: EXPERIMENTAL
Intervention: Enpatoran 50 mg
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Enpatoran 100 mg
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 37873786

Group type: EXPERIMENTAL
Intervention: Oncolytic reovirus treatment administered for 5 days every 28 days.
Number of subjects: 0
Study: 37873863

Group type: EXPERIMENTAL
Intervention: MEDI7247 (pyrrolobenzodiazepine antibody-drug conjugate)
Number of subjects: 0
Study: 37874020

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic-valve replacement (TAVR)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 1000
Study: 37874103

Group type: EXPERIMENTAL
Intervention: 2 grams of DHA per day
Number of subjects: 368

Group type: COMPARATOR
Intervention: Identically appearing placebo
Number of subjects: 368
Study: 37874110

Group type: EXPERIMENTAL
Intervention: Brain Health Support Program intervention for 45-weeks
Number of subjects: 350
Study: 37874111

Group type: EXPERIMENTAL
Intervention: Pioglitazone tablet
Number of subjects: 1330
Study: 37874403

Group type: EXPERIMENTAL
Intervention: Night shift load
Number of subjects: 730
Study: 37874574

Group type: EXPERIMENTAL
Intervention: Tongxinluo
Number of subjects: 3777

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3777
Study: 37874612

Group type: EXPERIMENTAL
Intervention: Managing Minds at Work (MMW) digital training intervention
Number of subjects: 224

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 224
Study: 37874619

Group type: EXPERIMENTAL
Intervention: Self-administered on the tablet app using a chatbot interface
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Administered by an in-person clinician
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Administered by a telehealth clinician
Number of subjects: 47
Study: 37874630

Group type: EXPERIMENTAL
Intervention: 20-week high-intensity strength training program
Number of subjects: 27
Study: 37874637

Group type: EXPERIMENTAL
Intervention: NOLA GEM (just-in-time adaptive mHealth intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: GEMA-alone (control)
Number of subjects: 60
Study: 37874657

Group type: EXPERIMENTAL
Intervention: Ambulatory patients (AMBU)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Hospitalized patients (HOSP)
Number of subjects: 79
Study: 37874655

Group type: EXPERIMENTAL
Intervention: High-resolution antropyloroduodenal manometry (HR-ADM) during postprandial period
Number of subjects: 60
Study: 37874831

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 870

Group type: COMPARATOR
Intervention: Fecal immunochemical testing (FIT)
Number of subjects: 870
Study: 37874908

Group type: EXPERIMENTAL
Intervention: TAVR + LAAO
Number of subjects: 349

Group type: COMPARATOR
Intervention: TAVR + medical therapy
Number of subjects: 349
Study: 37874913

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (mostly R-CHOP 75% and reduced dose R-CHOP 13%)
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: REALYSA cohort
Number of subjects: 645
Study: 37874963

Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study: 37875064

Group type: EXPERIMENTAL
Intervention: Amulet device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watchman device
Number of subjects: 0
Study: 37875144

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cemiplimab 350 mg intravenously every 3 weeks followed by curative-intent surgery
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cemiplimab followed by surgery
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Adjuvant cemiplimab
Number of subjects: 79
Study: 37875143

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 1579

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 1579
Study: 37875178

Group type: EXPERIMENTAL
Intervention: Group prenatal care
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Individual prenatal care
Number of subjects: 1256
Study: 37875310

Group type: EXPERIMENTAL
Intervention: Pantothenate kinase activation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37875323

Group type: EXPERIMENTAL
Intervention: Zimberelimab (240 mg every 2 weeks for 2 years)
Number of subjects: 105
Study: 37875337

Group type: EXPERIMENTAL
Intervention: Tai Chi training
Number of subjects: 330
Study: 37875429

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 37875494

Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab
Number of subjects: 0
Study: 37875524

Group type: EXPERIMENTAL
Intervention: Baseline FDG-PET/CT radiomics
Number of subjects: 0
Study: 37875559

Group type: EXPERIMENTAL
Intervention: Probiotic compound AB001 at single dose
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Probiotic compound AB001 at double dose
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 37875578

Group type: EXPERIMENTAL
Intervention: zuranolone 50 mg co-initiated with standard-of-care antidepressant therapy (ADT)
Number of subjects: 425

Group type: COMPARATOR
Intervention: placebo co-initiated with standard-of-care antidepressant therapy (ADT)
Number of subjects: 425
Study: 37875637

Group type: EXPERIMENTAL
Intervention: Chewable beetroot-based supplement (BR-CT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 44
Study: 37875714

Group type: EXPERIMENTAL
Intervention: Adalimumab reference product (adalimumab RP; Humira)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 695501
Number of subjects: 0
Study: 37875771

Group type: EXPERIMENTAL
Intervention: Alpelisib in combination with cetuximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpelisib-cetuximab combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetuximab monotherapy
Number of subjects: 0
Study: 37875792

Group type: EXPERIMENTAL
Intervention: Intermediate dose enoxaparin (60 mg for 45-60 kg, 80 mg for 61-100 kg, 100 mg for >100 kg) once daily for 14 days, with dose adjustment according to anti-factor Xa activity.
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Intermediate dose enoxaparin (IC)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Observational cohort (OC) receiving enoxaparin 40 mg/day
Number of subjects: 301
Study: 37875813

Group type: EXPERIMENTAL
Intervention: SAP group (50 patients)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: VAP group (10 patients)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Nonpneumonia group (104 patients)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Lower abundance of Streptococcus in SAP patients
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Increase in specific taxa in the phylum Actinobacteriota
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Oral microbiota model for SAP patients
Number of subjects: 164
Study: 37875818

Group type: EXPERIMENTAL
Intervention: Model 1 (clinicopathology and ultrasound)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Model 2 (clinicopathology, ultrasound, and PET)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Model 3 (clinicopathology, ultrasound, PET, and radiomics)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Positive axillary LNM group
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Radiomics score for predicting LNM (RS_LNM)
Number of subjects: 124
Study: 37875835

Group type: EXPERIMENTAL
Intervention: Software-based measurement-based care (MBC)
Number of subjects: 33
Study: 37875851

Group type: EXPERIMENTAL
Intervention: Structural intervention targeting school and parent levels
Number of subjects: 3100

Group type: EXPERIMENTAL
Intervention: Structural intervention combined with group-based Motivational Interviewing (group MI)
Number of subjects: 3100

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 3100
Study: 37875856

Group type: EXPERIMENTAL
Intervention: Tango-therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 31
Study: 37875869

Group type: EXPERIMENTAL
Intervention: PIPAC with cisplatin (10.5 mg/m2 in 150 mL NaCl 0.9%) and doxorubicin (2.1 mg/m2 in 50 mL NaCl 0.9%) followed by 2 cycles of FOLFOX every 6-7 weeks (total of 3 PIPACs and 6 cycles of FOLFOX).
Number of subjects: 0
Study: 37875943

Group type: EXPERIMENTAL
Intervention: VHW-led, CDSS-assisted T2D care model including lifestyle counselling, first-line oral antidiabetic, lipid-lowering, and antiplatelet treatment guided by a tablet-based CDSS.
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group receiving standard care by referral to a health facility for T2D management.
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: VHW-led, CDSS-assisted T2D care model.
Number of subjects: 226
Study: 37875962

Group type: EXPERIMENTAL
Intervention: Hans Kai program (intervention group, n=70)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard care (control group, n=35)
Number of subjects: 105
Study: 37875971

Group type: EXPERIMENTAL
Intervention: PT + MR (Mobility Rehab)
Number of subjects: 28

Group type: COMPARATOR
Intervention: PT alone
Number of subjects: 28
Study: 37875997

Group type: EXPERIMENTAL
Intervention: Microinvasive pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conbercept intravitreal injection (IVC)
Number of subjects: 102
Study: 37876018

Group type: EXPERIMENTAL
Intervention: HoNOS-13 questionnaire (13-item version including medication compliance)
Number of subjects: 609

Group type: COMPARATOR
Intervention: HoNOS-12 questionnaire (12-item version)
Number of subjects: 609
Study: 37876046

Group type: EXPERIMENTAL
Intervention: Damoctocog alfa pegol (prophylaxis every 3-4 days, median infusion dose of 37.5 IU/kg)
Number of subjects: 268
Study: 37876056

Group type: EXPERIMENTAL
Intervention: Computed tomography-guided nasotracheal intubation procedure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group A - easy intubation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group B - difficult intubation)
Number of subjects: 60
Study: 37876229

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (canagliflozin and dapagliflozin)
Number of subjects: 8483
Study: 37876374

Group type: EXPERIMENTAL
Intervention: Conservative oxygenation strategy (target arterial saturations 92-96%)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Liberal oxygenation strategy (target 97-100%)
Number of subjects: 300
Study: 37876540

Group type: EXPERIMENTAL
Intervention: Pasireotide monotherapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Pasireotide plus cabergoline
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Pasireotide monotherapy and combination therapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 68
Study: 37876731

Group type: EXPERIMENTAL
Intervention: HSK21542
Number of subjects: 0
Study: 37876886

Group type: EXPERIMENTAL
Intervention: Acacia 5 g daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Acacia 10 g daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Microcrystalline cellulose (MCC) 10 g daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All dietary treatment arms (Acacia 5 g/d, Acacia 10 g/d, MCC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 51
Study: 37876998

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (ULDCT)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 294
Study: 37877219

Group type: EXPERIMENTAL
Intervention: Third dose of ZF2001 after 3-4 months
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Third dose of ZF2001 after 5-6 months
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Third dose of ZF2001 after 7-9 months
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Heterologous BBIBP-CorV/ZF2001 prime-boost vaccination
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Older participants
Number of subjects: 480
Study: 37877260

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 37877369

Group type: EXPERIMENTAL
Intervention: Selumetinib treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 37877375

Group type: EXPERIMENTAL
Intervention: Pocock test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian Beta-Binomial models with weak priors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: O'Brien-Fleming test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-Binomial models with strong priors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified SPRT method
Number of subjects: 0
Study: 37877609

Group type: EXPERIMENTAL
Intervention: Sigh breaths plus usual care (sigh volumes producing plateau pressures of 35 cm H2O or 40 cm H2O for patients with BMI >35, delivered once every 6 minutes)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Sigh breaths plus usual care
Number of subjects: 524
Study: 37877585

Group type: EXPERIMENTAL
Intervention: Vitamin C administered intravenously every 6 hours for 96 hours (maximum of 16 doses)
Number of subjects: 2580

Group type: COMPARATOR
Intervention: Control (placebo or no vitamin C)
Number of subjects: 2580
Study: 37877800

Group type: EXPERIMENTAL
Intervention: B-cell receptor repertoire analysis using IGHV spectratyping and next-generation sequencing of peripheral blood B-cell genomic DNA
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: B-cell receptor repertoire analysis
Number of subjects: 14
Study: 37877913

Group type: EXPERIMENTAL
Intervention: M-TEER with the fourth-generation M-TEER device
Number of subjects: 1164
Study: 37878148

Group type: COMPARATOR
Intervention: Normal weight
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 1456
Study: 37878201

Group type: EXPERIMENTAL
Intervention: Religious fasting (intermittent fasting)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Five questionnaires
Number of subjects: 0
Study: 37878217

Group type: EXPERIMENTAL
Intervention: Promotora-based intervention (education, appointment reminders, assistance navigating the healthcare system)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Promotora-based intervention
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard-of-care alone
Number of subjects: 94
Study: 37878295

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in addition to optimal medical therapy
Number of subjects: 610

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Extent of viable myocardium
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Extent of nonviable myocardium
Number of subjects: 610
Study: 37878299

Group type: EXPERIMENTAL
Intervention: PVB-VATS
Number of subjects: 196

Group type: COMPARATOR
Intervention: PVB-US
Number of subjects: 196
Study: 37878305

Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreaticoduodenectomy
Number of subjects: 200
Study: 37878362

Group type: EXPERIMENTAL
Intervention: Web-based safety and health program
Number of subjects: 131
Study: 37878376

Group type: EXPERIMENTAL
Intervention: COMA-F intervention (mindfulness-based resiliency program)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: COMA-F intervention
Number of subjects: 15
Study: 37878483

Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU/day)
Number of subjects: 25671

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (1 g/day)
Number of subjects: 25671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25671
Study: 37878497

Group type: EXPERIMENTAL
Intervention: WARS1 levels in sepsis patients without monocytopenia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: WARS1 levels in sepsis patients (all patients)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: AUROC of WARS1 at admission for mortality in patients without monocytopenia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: AUROC of WARS1 at 24 h for mortality in patients without monocytopenia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: AUROC of CRP at admission for mortality in patients without monocytopenia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: AUROC of CRP at 24 h for mortality in patients without monocytopenia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: AUROC of procalcitonin at admission for mortality in patients without monocytopenia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: AUROC of procalcitonin at 24 h for mortality in patients without monocytopenia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: AUROC of WARS1 at admission for mortality in patients with monocytopenia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: AUROC of WARS1 at 24 h for mortality in patients with monocytopenia
Number of subjects: 74
Study: 37878624

Group type: EXPERIMENTAL
Intervention: GPC-100 + Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GPC-100
Number of subjects: 0

Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: G-CSF + Plerixafor
Number of subjects: 0
Study: 37878675

Group type: EXPERIMENTAL
Intervention: PRGN-2012 treatment at the highest dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRGN-2012 treatment
Number of subjects: 0
Study: 37878786

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy (90 mg twice daily) after <1 month of DAPT (n=1426)
Number of subjects: 2850

Group type: COMPARATOR
Intervention: Ticagrelor-based DAPT for 12 months (n=1424)
Number of subjects: 2850
Study: 37879047

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel) infusion (2 × 10^6 CAR T cells per kg) after leukapheresis and lymphodepleting chemotherapy
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel) infusion
Number of subjects: 104
Study: 37879077

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin administered at 0.6 mg/m2 on day 1 and 0.3 mg/m2 on day 8 of cycle 1, then at 0.3 mg/m2 on days 1 and 8 of cycles 2-6.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Number of subjects: 26
Study: 37879193

Group type: EXPERIMENTAL
Intervention: Closed IV catheter system (BD Nexiva™)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Peripheral open IV catheter (BD Insyte™ Autoguard™)
Number of subjects: 38
Study: 37879242

Group type: EXPERIMENTAL
Intervention: Virtual-reality exposure treatment (VRET)
Number of subjects: 186
Study: 37879393

Group type: EXPERIMENTAL
Intervention: Returning genetic results on arsenic metabolism efficiency to inefficient metabolizers (high-risk)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Returning genetic results on arsenic metabolism efficiency to efficient metabolizers (low-risk)
Number of subjects: 309

Group type: COMPARATOR
Intervention: One-on-one educational intervention (baseline information on arsenic effects and exposure reduction)
Number of subjects: 309
Study: 37879490

Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 2008

Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 2008
Study: 37879536

Group type: EXPERIMENTAL
Intervention: Ivonescimab 10 mg/kg Q3W
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Ivonescimab 20 mg/kg Q2W
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Ivonescimab 20 mg/kg Q3W
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Ivonescimab 30 mg/kg Q3W
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Ivonescimab (all doses)
Number of subjects: 108
Study: 37879695

Group type: EXPERIMENTAL
Intervention: ASTX727 (demethylating agent)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 27
Study: 37879700

Group type: EXPERIMENTAL
Intervention: CURATE.AI COR-Tx platform intervention, 10-week personalized digital intervention, three times a week
Number of subjects: 15
Study: 37879701

Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention for family carers (administered in 2-hour sessions over 9 weeks)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Service utilisation measured during a 12-month period preintervention, a 12-month period postintervention, and during a 12-24-month period post-intervention
Number of subjects: 111
Study: 37879858

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 121

Group type: COMPARATOR
Intervention: Exercise with optional delayed surgery
Number of subjects: 121
Study: 37879880

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR) and index of microvascular resistance (IMR) measured in the culprit vessel after primary percutaneous coronary intervention.
Number of subjects: 102
Study: 37879886

Group type: EXPERIMENTAL
Intervention: NUC-treated patients
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Untreated HBeAg(+) patients
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Untreated HBeAg(-) patients
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Untreated chronic infection patients
Number of subjects: 152

Group type: COMPARATOR
Intervention: Undetectability of cirB-RNA
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Combined undetectability of cirB-RNA and HBcrAg in untreated HBeAg(-) patients
Number of subjects: 152
Study: 37880023

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT)
Number of subjects: 26025
Study: 37880076

Group type: EXPERIMENTAL
Intervention: No adjuvant therapy for patients with longitudinal undetectable MRD
Number of subjects: 180